Suppliers and packagers for EPITOL

EPITOL

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Teva	EPITOL	carbamazepine	TABLET;ORAL	070541	ANDA	Teva Pharmaceuticals USA, Inc.	0093-0090-01	100 TABLET in 1 BOTTLE (0093-0090-01)	1990-09-30
Teva	EPITOL	carbamazepine	TABLET;ORAL	070541	ANDA	Teva Pharmaceuticals USA, Inc.	0093-0109-10	1000 TABLET in 1 BOTTLE (0093-0109-10)	1990-09-30
Teva	EPITOL	carbamazepine	TABLET;ORAL	070541	ANDA	Bryant Ranch Prepack	63629-8753-1	1000 TABLET in 1 BOTTLE (63629-8753-1)	1990-09-30

Suppliers and packagers for EPITOL

Last updated: May 31, 2026

Epitol (Carbamazepine) Suppliers and Manufacturer Landscape: What Companies Make It Globally

Epitol is a brand name for carbamazepine, an oral antiepileptic drug. The supplier set is dominated by API manufacturers of carbamazepine and finished-dose manufacturers producing tablets or extended-release products under regional brand/marketing authorizations.

Carbamazepine is widely genericized. That means “suppliers for Epitol” depends on the market you mean (US, EU, MENA, LATAM, India) and whether you’re sourcing API or finished dosage. Broadly, the supplier universe falls into two tiers: (1) API makers and (2) formulation/packaging and marketing authorization holders for specific finished products sold under brand or generic labels.

Who supplies Epitol (carbamazepine) API and finished-dose tablets?

Typical supply chain for carbamazepine (Epitol)

Carbamazepine supply usually runs:

• Carbamazepine API synthesis and purification (chemical manufacturers)
• Formulation and tableting (drug product manufacturers)
• Packaging (secondary packaging and blistering/bottling)
• Regulatory release under local marketing authorization

Where supplier lists usually come from

For finished-dose Epitol and generic carbamazepine, supplier identification is typically derived from:

• Local drug registration databases (marketing authorization holders)
• Customs/importer records
• Tender bid databases (government procurement)
• CDSCO/EMA/PIC/S-type quality compliance documentation where accessible
• API supplier disclosures in DMFs and commercial questionnaires

Given the breadth of carbamazepine’s global genericization, the most actionable supplier mapping requires a market-specific Orange Book-equivalent and registration dataset, which is not provided here.

What companies supply carbamazepine API (key global manufacturers)?

API supplier categories

API makers are generally:

• Large-scale chemical manufacturers with multiple commercial routes and stringent quality systems
• Specialized API producers with DMF coverage in multiple jurisdictions
• Contract manufacturers that supply customer-specific grades and documentation packages

Market reality for carbamazepine

Carbamazepine is mature, inexpensive, and sourced from numerous suppliers across Asia, Europe, and the Middle East. Competitive factors that determine “best supplier” include:

• DMF/CEP availability for target markets
• polymorph control and particle size ranges for formulation performance
• residual solvent and impurity profiles (ICH Q3A/Q3B alignment)
• stability data for tablet and/or suspension products
• ability to meet regulatory inspections (GMP compliance)

Which manufacturers produce Epitol-branded tablets in specific countries?

Country matters

Epitol is historically associated with specific originators, but current “Epitol” supply in many countries is often maintained through:

• license holders/brand owners with contracted manufacturers
• parallel import channels
• generic equivalents marketed under the same brand name in some jurisdictions

Without the target country or the specific dosage form (immediate-release vs extended-release), a definitive manufacturer list for “Epitol” cannot be produced accurately.

Does Epitol come in extended-release or immediate-release formats, and who supplies each?

Formulation split

Carbamazepine is commonly supplied as:

• Immediate-release tablets
• Extended-release (XR) / prolonged-release tablets or capsules in some markets

Supplier selection differs because XR products require:

• distinct excipient systems
• dissolution specification control
• tablet coating or matrix technologies

A global supplier list that treats Epitol as one product line can be misleading.

What patent status affects sourcing of Epitol (carbamazepine) generics?

Carbamazepine is long off-patent in most jurisdictions. As a result:

• Epitol supply and sourcing typically face no exclusivity barriers at the molecule level.
• Competitive pressure centers on quality, impurity profiles, and supply reliability, not patent exclusivity.

However, some markets may still have protection around:

• specific formulations
• specific processes
• specific extended-release constructions
• pediatric or specific label claims

What regulatory status affects which suppliers can sell carbamazepine?

Typical regulatory gates

For market entry, suppliers must satisfy:

• GMP inspection expectations (PIC/S alignment in many regions)
• documentation availability for impurities and residual solvents
• bioequivalence requirements where applicable (for generic drug product)
• local pharmacovigilance participation for the marketing authorization holder

DMF and CEP-driven supplier eligibility

API suppliers are often selected based on:

• registered DMFs
• CEPs or equivalent certificates (Europe)
• validated impurity profiles consistent with local pharmacopoeias

How do you evaluate suppliers for carbamazepine (Epitol) for procurement or licensing?

Evaluation checklist that drives supplier selection

• Regulatory file readiness (DMF/CEP, documentation completeness)
• GMP compliance history and inspection record
• Release and testing capability (HPLC/GC methods aligned to pharmacopeia specs)
• Stability and shelf-life (real-time and accelerated results)
• Supply continuity (capacity, lead times, batch release predictability)
• Change control maturity (process updates without regulatory friction)

Key Takeaways

• Epitol is carbamazepine; supplier ecosystems are extensive because the drug is largely genericized.
• “Suppliers for Epitol” is market- and dosage-form-specific; procurement decisions hinge on whether you need API or finished tablets and whether the product is immediate-release or extended-release.
• The most actionable supplier identification is built from local marketing authorization holders plus API DMF/CEP-linked manufacturers, then filtered by GMP and documentation readiness.

FAQs

1) Who are the main carbamazepine API supplier types in global procurement?

Large API producers with DMF/CEP coverage, plus contract API manufacturers offering regulatory-ready impurity and solvent profiles.

2) Can Epitol be sourced from multiple countries without GMP risk?

Quality risk depends on regulatory standing and GMP history of the manufacturer and the marketing authorization holder in the destination market.

3) What specs matter most when switching carbamazepine API suppliers?

Impurity profile alignment, polymorphic form control, residual solvents, particle size, and dissolution-relevant characteristics.

4) Do extended-release carbamazepine products use different suppliers than immediate-release?

Usually yes, because extended-release tablet performance relies on distinct excipient systems and manufacturing technology.

5) How do procurement teams validate new carbamazepine suppliers quickly?

By mapping DMF/CEP documentation, reviewing GMP inspection outcomes, and qualifying through lab testing against pharmacopoeia and internal dissolution/assay specs.

References

1. (No citable sources were provided in the prompt to support a factual supplier list.)